An Experimental Generator for Production of High-Purity<sup>212</sup>Pb for Use in Radiopharmaceuticals-Reference-Cited by-同舟云学术

An Experimental Generator for Production of High-Purity²¹²Pb for Use in Radiopharmaceuticals

Published:2022-07-07 Issue:1 Volume:64 Page:173-176
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Li Ruth Gong,Stenberg Vilde Yuli,Larsen Roy Hartvig

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference18 articles.

1. Application of 212Pb for targeted α-particle therapy (TAT): pre-clinical and mechanistic understanding through to clinical translation;Yong;AIMS Med Sci,2015

2. An improved generator for the production of 212Pb and 212Bi from 224Ra

3. Methodology for labeling proteins and peptides with lead-212 (212Pb)

4. Torgue J Maquaire P Yong J ., inventors; Orano Med SAS, assignee. Method and apparatus for the production of lead 212 for medical use. U.S. Patent US11037690B2. June 15, 2021.

5. Automated cassette-based production of high specific activity [(203/212Pb)Pb]peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer;Li;Appl Radiat Isot,2017

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Method and mechanism for efficient radium isolation from bulk thorium based on anion exchange;Chemical Engineering Journal;2024-09

2. Efficient separation of radium from natural thorium using a mesoporous silica-supported composite resin with sulfonic acid groups for the acquisition of targeted α-nuclides 212Pb;Chemical Engineering Journal;2024-04

3. Targeted Radium Alpha Therapy in the Era of Nanomedicine: In Vivo Results;International Journal of Molecular Sciences;2024-01-04

4. Is²¹²Pb Really Happening? The Post-¹⁷⁷Lu/²²⁵Ac Blockbuster?;Journal of Nuclear Medicine;2024-01-04

5. Exploring the use of rigid 18-membered macrocycles with amide pendant arms for Pb(ii)-based radiopharmaceuticals;Inorganic Chemistry Frontiers;2024